New investigational drug for treatment of ovarian cancer

Trial ID:
IRB-25-8585
Jo Marie Tran Janco, MD

Inclusion Criteria

Patients must:

  • Be 18 years old or older
  • Have histological confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma
  • Be newly diagnosed FIGO Stage III or IV
  • Have adequate tumor tissue sample available for testing

Exclusion Criteria

Patients must not:

  • Have a BRCA mutation
  • Be pregnant or breastfeeding
  • Have evidence of ongoing bowel obstruction
  • Have anu autoimmune disorders
  • Have evidence of bleeding diathesis

Additional Info

All treatments and physical visit during this study will take place at Prebys Cancer Center in Hillcrest.

NCT #06819007

Study duration is expected to occur over 20 months.

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org